FHD-286

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
144 patients (estimated)
Sponsors
Foghorn Therapeutics Inc.
Tags
BRG1 Inhibitor, BRM Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1860
NCT Identifier
NCT04891757

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.